Assignee
PIERIS PHARMACEUTICALS GMBH
DE·35 granted patents·17 pending applications·99 citations·filing 2012–2022
Top patents by PatentIndex Score
52 records- 0193US10857202B2Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Dec 8, 2020·4 cites·18 claims
- 0292US11382951B2Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2020·Granted Jul 12, 2022·2 cites·19 claims
- 0392US11345728B2Specific-binding polypeptides and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2020·Granted May 31, 2022·2 cites·14 claims
- 0492US10526382B2Human neutrophil gelatinase-associated lipocalin (hNGAL) muteins capable of binding angiopoietin-2 (Ang-2) and methods of use thereofPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Jan 7, 2020·6 cites·47 claims
- 0591US10618941B2Muteins of human lipocalin 2 (Lcn2,hNGAL) with affinity for a given targetPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Apr 14, 2020·6 cites·20 claims
- 0690US10016483B2Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Jul 10, 2018·6 cites·20 claims
- 0789US10273275B2Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereofPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Apr 30, 2019·10 cites·20 claims
- 0889US10046027B2Muteins of tear lipocalin and methods for obtaining the samePIERIS PHARMACEUTICALS GMBH·Filed 2015·Granted Aug 14, 2018·8 cites·14 claims
- 0988US10774119B2Specific-binding polypeptides and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2015·Granted Sep 15, 2020·3 cites·13 claims
- 1087US11773147B2Lipocalin muteins with binding affinity for LAG-3PIERIS PHARMACEUTICALS GMBH·Filed 2021·Granted Oct 3, 2023·1 cites·20 claims
- 1187US10526384B2Interleukin-17A-specific and interleukin-23-specific binding polypeptides and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2013·Granted Jan 7, 2020·5 cites·16 claims
- 1287US10398754B2Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2018·Granted Sep 3, 2019·4 cites·19 claims
- 1387US9687524B2Tear lipocalin muteins binding IL-4 R alphaPIERIS PHARMACEUTICALS GMBH·Filed 2015·Granted Jun 27, 2017·6 cites·7 claims
- 1485US11919931B2Anti-cancer fusion polypeptide capable of binding both CD137 and glypican-3 (GPC3)PIERIS PHARMACEUTICALS GMBH·Filed 2021·Granted Mar 5, 2024·1 cites·6 claims
- 1583US10501510B2Muteins of human tear lipocalin capable of binding lymphocyte-activation gene 3 (LAG-3) and methods of use thereofPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Dec 10, 2019·4 cites·23 claims
- 1683US10232014B2Tear lipocalin muteins binding IL-4 R alphaPIERIS PHARMACEUTICALS GMBH·Filed 2017·Granted Mar 19, 2019·3 cites·25 claims
- 1783US9572863B2Methods for preventing or treating certain disorders by inhibiting binding of IL-4 and/or IL-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2012·Granted Feb 21, 2017·4 cites·20 claims
- 1882US11261221B2Proteins specific for CD137PIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Mar 1, 2022·2 cites·12 claims
- 1982US10400016B2Proteins specific for calcitonin gene-related peptidePIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Sep 3, 2019·4 cites·25 claims
- 2082US9950034B2Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulationPIERIS PHARMACEUTICALS GMBH·Filed 2017·Granted Apr 24, 2018·3 cites·20 claims
- 2182US9610356B2Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulationPIERIS PHARMACEUTICALS GMBH·Filed 2012·Granted Apr 4, 2017·7 cites·23 claims
- 2280US10927156B2Human tear lipocalin muteins which specifically bind lymphocyte activation gene-3 (LAG3) and method of use thereof to stimulate an immune responsePIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Feb 23, 2021·1 cites·10 claims
- 2379US2023021168A1Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptorsPIERIS PHARMACEUTICALS GMBH·Filed 2022·Application pending·0 cites
- 2477US11382963B2Engineered T cells and uses thereforPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Jul 12, 2022·1 cites·5 claims
- 2575US11034737B2Proteins specific for calcitonin gene-related peptidePIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Jun 15, 2021·1 cites·17 claims
- 2675US10947284B2Fusion moleculesPIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Mar 16, 2021·1 cites·22 claims
- 2774US11168119B2Lipocalin muteins with binding affinity for LAG-3PIERIS PHARMACEUTICALS GMBH·Filed 2018·Granted Nov 9, 2021·1 cites·28 claims
- 2872US12195503B2Proteins specific for CD137PIERIS PHARMACEUTICALS GMBH·Filed 2022·Granted Jan 14, 2025·0 cites·17 claims
- 2971US10913778B2Anti-cancer fusion polypeptides, encoding nucleic acids and methods of using polypeptidesPIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Feb 9, 2021·1 cites·33 claims
- 3071US10865250B2Anti-cancer fusion polypeptidePIERIS PHARMACEUTICALS GMBH·Filed 2016·Granted Dec 15, 2020·1 cites·8 claims
- 3168US2022296690A1Engineered t cells and uses thereforPIERIS PHARMACEUTICALS GMBH·Filed 2022·Application pending·0 cites
- 3266US10927154B2Multi-specific polypeptide useful for localized tumor immunomodulationPIERIS PHARMACEUTICALS GMBH·Filed 2015·Granted Feb 23, 2021·1 cites·6 claims
- 3364US11827681B2Muteins of human lipocalin 2 (Lcn2, hNGAL) with affinity for a given targetPIERIS PHARMACEUTICALS GMBH·Filed 2020·Granted Nov 28, 2023·0 cites·21 claims
- 3463US11034738B2Nucleic acid molecules encoding human neutrophil gelatinase-associated lipocalin (hNGAL) which bind angiopoietin-2 (Ang-2)PIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Jun 15, 2021·0 cites·18 claims
- 3560US10787491B2Nucleic acid molecules encoding muteins of human lipocalin 2 with affinity for glypican-3 (GPC3)PIERIS PHARMACEUTICALS GMBH·Filed 2019·Granted Sep 29, 2020·0 cites·11 claims
- 3660US2020148733A1Novel interleukin-17a-specific and interleukin-23-specific binding polypeptides and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2019·Application pending·0 cites
- 3759US2021198380A1Anti-cancer fusion polypeptidePIERIS PHARMACEUTICALS GMBH·Filed 2020·Application pending·0 cites
- 3859US2019015477A1Muteins of tear lipocalin and methods for obtaining the samePIERIS PHARMACEUTICALS GMBH·Filed 2018·Application pending·0 cites
- 3956US2017066807A1Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3PIERIS PHARMACEUTICALS GMBH·Filed 2016·Application pending·0 cites
- 4055US2018311311A1Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulationPIERIS PHARMACEUTICALS GMBH·Filed 2018·Application pending·0 cites
- 4152US2017369542A1Human neutrophil gelatinase-associated lipocalin (hngal) muteins that bind hepcidin and nucleic acid encoding suchPIERIS PHARMACEUTICALS GMBH·Filed 2017·Application pending·0 cites
- 4251US2024166763A1Her2/4-1bb bispecific fusion proteins for the treatment of cancerPIERIS PHARMACEUTICALS GMBH·Filed 2020·Application pending·0 cites
- 4351US2024228562A1Novel lipocalin muteins specific for connective tissue growth factor (ctgf)PIERIS PHARMACEUTICALS GMBH·Filed 2022·Application pending·0 cites
- 4451US2024166764A1Her2/4-1bb bispecific fusion proteins for the treatment of cancerPIERIS PHARMACEUTICALS GMBH·Filed 2022·Application pending·0 cites
- 4550US2023227568A1Multimeric immunomodulator targeting 4-1bbPIERIS PHARMACEUTICALS GMBH·Filed 2021·Application pending·0 cites
- 4650US2023366884A1Biomarker methods and usesPIERIS PHARMACEUTICALS GMBH·Filed 2021·Application pending·0 cites
- 4749US9751920B2Muteins with tear lipocalin having affinity to human c-met receptor tyrosine kinase and methods for obtaining the samePIERIS PHARMACEUTICALS GMBH·Filed 2015·Granted Sep 5, 2017·0 cites·2 claims
- 4847US2021363257A1Novel fusion protein specific for cd137 and pd-l1PIERIS PHARMACEUTICALS GMBH·Filed 2019·Application pending·0 cites
- 4946US2021246219A1Combination therapies comprising cd137/her2 bispecific agents and pd-1 axis inhibitors and uses thereofPIERIS PHARMACEUTICALS GMBH·Filed 2019·Application pending·0 cites
- 5045US12486330B2Fusion proteins specific for CD137 and GPC3PIERIS PHARMACEUTICALS GMBH·Filed 2020·Granted Dec 2, 2025·0 cites·6 claims
Showing the top 50 of 52 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →